Advertisement

Acne-Mimicking Diseases

  • Gerd Plewig
  • Bodo Melnik
  • WenChieh Chen
Chapter

Abstract

In this chapter, dealing with a variety of diseases looking like acne, a number of terminologies are used in the international literature, including acneiform, acneform, acne-like, and acne mimicking, in an analogous way.

Bibliography

Drug-Induced Acne

  1. Ben-Amitai D, Laron Z. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne. J Eur Acad Dermatol Venereol. 2011;25:950–4.PubMedGoogle Scholar
  2. Blatt J, Lee PA. Severe acne and hyperandrogenemia following dactinomycin. Med Pediatr Oncol. 1993;21:373–4.PubMedGoogle Scholar
  3. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005;141:333–8.PubMedGoogle Scholar
  4. Collomp K, Buisson C, Lasne F, Collomp R. DHEA, physical exercise and doping. J Steroid Biochem Mol Biol. 2015;145:206–12.PubMedGoogle Scholar
  5. Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol. 1989;125:571–2.PubMedGoogle Scholar
  6. Kazandjieva J, Tsankov N. Drug-induced acne. Clin Dermatol. 2017;35:156–62.PubMedGoogle Scholar
  7. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol (Oxf). 1998;48:81–7.Google Scholar
  8. Kraus SL, Emmert S, Schön MP, Haenssle HA. The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol. 2012;148:1210–2.PubMedGoogle Scholar
  9. Melnik BC. Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes. 2009;16:218–23.PubMedGoogle Scholar
  10. Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol. 2009;18:833–41.PubMedGoogle Scholar
  11. Melnik B, Jansen T, Grabbe S. Anabolikamissbrauch und Bodybuilding-Akne: eine unterschätzte gesundheitliche Gefährdung. J Dtsch Dermatol Ges. 2007;5:110–7.PubMedGoogle Scholar
  12. Pronsato L, Milanesi L, Vasconsuelo A, La Colla A. Testosterone modulates FoxO3a and p53-related genes to protect C2C12 skeletal muscle cells against apoptosis. Steroids. 2017;124:35–45.PubMedGoogle Scholar
  13. Ren W, Yin J, Duan J, et al. mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets. Eur J Immunol. 2016;46:291–9.PubMedGoogle Scholar
  14. Saad F, Röhrig G, von Haehling S, Traish A. Testosterone deficiency and testosterone treatment in older men. Gerontology. 2017;63:144–56.PubMedGoogle Scholar
  15. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol. 2008;128:1286–93.Google Scholar
  16. Smurawa TM, Congeni JA. Testosterone precursors: use and abuse in pediatric athletes. Pediatr Clin North Am. 2007;54:787–96.PubMedGoogle Scholar
  17. Vora S, Ovhal A, Jerajani H, et al. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol. 2008;159:990–1.PubMedGoogle Scholar

Drug-Induced Acneiform Eruptions

  1. Acharyya S, Sau S, Dasgupta P, et al. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer—a retrospective study. J Indian Med Assoc. 2012;110:474–6.PubMedGoogle Scholar
  2. Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55:250–4.PubMedGoogle Scholar
  3. Anforth R, Carlos G, Clements A, et al. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172:239–43.PubMedGoogle Scholar
  4. Balta I, Ozuguz P. Vitamin B12-induced acneiform eruption. Cutan Ocul Toxicol. 2014;33:94–5.PubMedGoogle Scholar
  5. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15:249–59.PubMedGoogle Scholar
  6. Bencini PL, Montagnino G, Sala F, et al. Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients. Dermatologica. 1986;172:24–30.PubMedGoogle Scholar
  7. Bettoli V, Trimurti S, Lombardi AR, Virgili A. Acne due to amineptine abuse. J Eur Acad Dermatol Venereol. 1998;10:281–3.PubMedGoogle Scholar
  8. Bettoli V, Zauli S, Montis A, et al. Acneiform eruption due to vitamin B12: a problem still unsolved. G Ital Dermatol Venereol. 2014;149:153–5.PubMedGoogle Scholar
  9. Bock KW. Toward elucidation of dioxin-mediated chloracne and Ah receptor functions. Biochem Pharmacol. 2016;112:1–115.PubMedGoogle Scholar
  10. Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103–9.PubMedGoogle Scholar
  11. Chan HH, Wing Y, Su R, et al. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord. 2000;57:107–13.PubMedGoogle Scholar
  12. Cohen LK, George W, Smith R. Isoniazid induced acne and pellagra. Occurrence in slow inactivators of isoniazid. Arch Dermatol. 1974;109:377–81.PubMedGoogle Scholar
  13. De Gálvez Aranda MV, Sánchez PS, Alonso Corral MJ, et al. Acneiform eruption caused by amineptine. A case report and review of the literature. J Eur Acad Dermatol Venereol. 2001;15:337–9.PubMedGoogle Scholar
  14. Dessinioti C, Antoniou C, Katsambas A. Acneiform eruptions. Clin Dermatol. 2014;32:24–34.PubMedGoogle Scholar
  15. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007;56:500–5.PubMedGoogle Scholar
  16. Du-Thanh A, Kluger N, Bensalleh H, Guillot B. Drug-induced acneiform eruption. Am J Clin Dermatol. 2011;12:233–45.PubMedGoogle Scholar
  17. Fabbrocini G, Panariello L, Caro G, Cacciapuoti S. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Skin Appendage Disord. 2015;1:31–7.PubMedPubMedCentralGoogle Scholar
  18. Han SS, Lee M, Park GH, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol. 2010;162:371–9.PubMedGoogle Scholar
  19. Harrell BL, Rudolph AH. Kelp diet: a cause of acneiform eruption. Arch Dermatol. 1976;112:560.PubMedGoogle Scholar
  20. Herbst RS, LoRusso PM, Purdom M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer. 2003;4:366–9.PubMedGoogle Scholar
  21. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317–26.PubMedGoogle Scholar
  22. Khanna S, Chirinos RE, Venna S. Escitalopram oxalate (Lexapro)-induced acneiform eruption. J Am Acad Dermatol. 2012;67:e261–3.PubMedGoogle Scholar
  23. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69:463–72.PubMedGoogle Scholar
  24. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46:291–8.PubMedPubMedCentralGoogle Scholar
  25. Levandoski KA, Girardi NA, Loss MJ. Eruptive sebaceous hyperplasia as a side effect of oral tacrolimus in a renal transplant recipient. Dermatol Online J. 2017;23(5).Google Scholar
  26. Li AW, Antaya RJ. Isotretinoin-induced acne fulminans without systemic symptoms with concurrent exuberant granulation tissue. Pediatr Dermatol. 2018;35:257–8.PubMedGoogle Scholar
  27. Liu Z, Choi SW, Crott JW, et al. Multiple B-vitamin inadequacy amplifies alterations induced by folate depletion in p53 expression and its downstream effector MDM2. Int J Cancer. 2008;123:519–25.PubMedPubMedCentralGoogle Scholar
  28. Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol. 2006;55:139–42.PubMedGoogle Scholar
  29. Martín JM, Jordá E, Monteagudo C, et al. Follicular acneiform eruption induced by imatinib. J Eur Acad Dermatol Venereol. 2006;20:1368–70.PubMedGoogle Scholar
  30. Melnik BC. The P450 system and mTORC1 signalling in acne. Exp Dermatol. 2014;23:318–9.PubMedGoogle Scholar
  31. Melnik BC. p53: key conductor of all anti-acne therapies. J Transl Med. 2017;15:195.PubMedPubMedCentralGoogle Scholar
  32. Nakahara T, Moroi Y, Takayama K, et al. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. Onco Targets Ther. 2015;8:259–63.PubMedPubMedCentralGoogle Scholar
  33. Oztas P, Aksakal AB, Oztas MO, Onder M. Severe acne with lithium. Ann Pharmacother. 2001;35:961–2.PubMedGoogle Scholar
  34. Requena C, Llombart B, Sanmartín O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis. 2012;90:77–80.PubMedGoogle Scholar
  35. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer. Part II. Targeted therapies. J Am Acad Dermatol. 2014;71:217e1–11.Google Scholar
  36. Ricci F, Paradisi A, Masini F, et al. Acneiform eruption induced by ethosuximide. Eur J Dermatol. 2014;24:98–9.PubMedGoogle Scholar
  37. Richter A, Beideck S, Bender W, Frosch PJ. Epidermalzysten und Follikulitiden durch Cyclosporin A. Hautarzt. 1993;44:521–3.PubMedGoogle Scholar
  38. Sinha S, Udupa S, Bhandary RP, et al. Sertraline-induced acneiform eruption. J Neuropsychiatry Clin Neurosci. 2014;26:E56–7.PubMedGoogle Scholar
  39. Strahan JE, Burch JM. Cyclosporine-induced infantile nodulocystic acne. Arch Dermatol. 2009;145:797–9.PubMedGoogle Scholar
  40. Takata T, Tarutani M, Zouboulis CC, Sano S. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. J Dermatol Sci. 2012;66:165–8.PubMedGoogle Scholar
  41. Tanusree P, Schumann C, Rüdiger S, et al. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer. 2014;50:1855–63.Google Scholar
  42. Vanneste L, Wolter P, Van den Oord JJ, et al. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol. 2015;29:61–8.PubMedGoogle Scholar
  43. Vaubel J, Livingstone E, Schadendorf D, Zimmer L. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venereol. 2014;28:1685–9.PubMedGoogle Scholar
  44. Wollina U, Kammler HJ, Hesselbarth N, et al. Ecstasy pimples—a new facial dermatosis. Dermatology. 1998;197:171–3.PubMedGoogle Scholar

Acne venenata

  1. Abou-ElWafa HS, Albadry AA, El-Gilany AH, Ismael AF. Dermatoses among automobile mechanics in Mansoura, Egypt. Arch Environ Occup Health. 2018;73:42–7.PubMedGoogle Scholar
  2. American Academy of Dermatology invitational symposium on comedogenicity. J Am Acad Dermatol. 1990;20:272–7.Google Scholar
  3. Draelos ZD, DiNardo JC. A re-evaluation of the comedogenicity concept. J Am Acad Dermatol. 2006;54:507–12.PubMedGoogle Scholar
  4. Fisher AA. Acne venenata in black skin. Cutis. 1986;37:24–6.PubMedGoogle Scholar
  5. Kaidbey KH, Kligman AM. A human model of coal tar acne. Arch Dermatol. 1974;109:212–5.PubMedGoogle Scholar
  6. Kligman AM. Updating the rabbit ear comedogenic assay. In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz; 1989. p. 97–106.Google Scholar
  7. Kligman AM. A critical look at acne cosmetica. J Cutan Aging Cosmet Dermatol. 1988/89;1:109–14.Google Scholar
  8. Kligman AM, Mills OH Jr. “Acne cosmetica”. Arch Dermatol. 1972;106:843–50.PubMedGoogle Scholar
  9. Mills OH Jr, Kligman AM. Comedogenicity of sunscreens: experimental observations in rabbits. Arch Dermatol. 1982;118:417–9.PubMedGoogle Scholar
  10. Nguyen SH, Dang TP, Maibach HI. Comedogenicity in rabbit: some cosmetic ingredients/vehicles. Cutan Ocul Toxicol. 2007;26:287–92.PubMedGoogle Scholar
  11. Plewig G, Fulton JE, Kligman AM. Pomade acne. Arch Dermatol. 1970;101:580–4.PubMedGoogle Scholar
  12. Shelley WB, Shelley ED. Chap stick acne. Cutis. 1986;37:459–60.PubMedGoogle Scholar
  13. Singh S, Mann BK, Tiwary NK. Acne cosmetica revisited: a case-control study shows a dose-dependent inverse association between overall cosmetic use and post-adolescent acne. Dermatology. 2013;226:337–41.PubMedGoogle Scholar
  14. Verhagen AR. Pomade acne in black skin. Arch Dermatol. 1974;110:465.PubMedGoogle Scholar

Acne Mechanica

  1. Basler RS. Acne mechanica in athletes. Cutis. 1992;50:125–8.PubMedGoogle Scholar
  2. Brun P, Baran R. Une acné mécanique méconnue: la dermatite du cou des violoinistes. Ann Dermatol Venereol. 1984;111:241–5.PubMedGoogle Scholar
  3. Darley CR. Acne conglobata of the buttocks aggravated by mechanical and environmental factors. Clin Exp Dermatol. 1990;15:462–3.PubMedGoogle Scholar
  4. Gentile DA, Bailey K, Bavelier D, et al. Internet gaming disorder in children and adolescents. Pediatrics. 2017;140(Suppl 2):S81–5.PubMedGoogle Scholar
  5. Kang YC, Choi EH, Hwang SM, et al. Acne mechanica due to an orthopedic crutch. Cutis. 1999;64:97–8.PubMedGoogle Scholar
  6. Knierim C, Goertz W, Reifenberger J, et al. Geigerknoten. Hautarzt. 2013;64:724–6.PubMedGoogle Scholar
  7. Mills OH Jr, Kligman A. Acne mechanica. Arch Dermatol. 1975a;111:481–3.PubMedGoogle Scholar
  8. Petrozzi JW. Comb and brush acne. Cutis. 1980;26:568–71.PubMedGoogle Scholar
  9. Strauss RM, Harrington CI. Stump acne: a new variant of acne mechanica and a cause of immobility. Br J Dermatol. 2001;144:647–8.PubMedGoogle Scholar

Chloracne

  1. Birnbaum LS. The mechanism of dioxin toxicity: relationship to risk assessment. Environ Health Perspect. 1994;102(Suppl 9):157–67.PubMedPubMedCentralGoogle Scholar
  2. Bettmann S. Chlorakne, eine besondere Form von professioneller Hauterkrankung. Dtsch Med Wochenschr. 1901;27:437–40.Google Scholar
  3. Bock KW. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-mediated deregulation of myeloid and sebaceous gland stem/progenitor cell homeostasis. Arch Toxicol. 2017;91:2295–301.PubMedGoogle Scholar
  4. Budnik LT, Wegner R, Rogall U, Baur X. Accidental exposure to polychlorinated biphenyls (PCB) in waste cargo after heavy seas. Global waste transport as a source of PCB exposure. Int Arch Occup Environ Health. 2014;87:125–35.PubMedGoogle Scholar
  5. Caputo R, Monti M, Ermacora E, et al. Cutaneous manifestations of tetrachlorodibenzo-p-dioxin in children and adolescents: follow-up 10 years after the Seveso, Italy, accident. J Am Acad Dermatol. 1988;19:812–9.PubMedGoogle Scholar
  6. Coenraads PJ, Brouwer A, Olie K, Tang N. Chloracne: some recent issues. Dermatol Clin. 1994;12:569–76.PubMedGoogle Scholar
  7. Cole GW, Stone O, Gates D, Culver D. Chloracne from pentachlorophenol-preserved wood. Contact Dermatitis. 1986;15:164–8.PubMedGoogle Scholar
  8. Crow KD. Chloracne and its potential clinical implications. Clin Exp Dermatol. 1981;6:243–57.PubMedGoogle Scholar
  9. Dunagin WG. Cutaneous signs of systemic toxicity due to dioxins and related chemicals. J Am Acad Dermatol. 1984;10:688–700.PubMedGoogle Scholar
  10. Geusau A, Tschachler E, Meixner M, et al. Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Lancet. 1999;354:1266–7.PubMedGoogle Scholar
  11. Geusau A, Abraham K, Geissler K, et al. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects. Environ Health Perspect. 2001;109:865–9.PubMedPubMedCentralGoogle Scholar
  12. Gladen BC, Taylor JS, Wu YC, et al. Dermatological findings in children exposed transplacentally to heat-degraded polychlorinated biphenyls in Taiwan. Br J Dermatol. 1990;122:799–808.PubMedGoogle Scholar
  13. Goldmann PJ. Schwerste akute Chloracne, eine Massenintoxikation durch 2,3,6,7-Tetrachlordibenzodioxin. Hautarzt. 1973;24:149–52.PubMedGoogle Scholar
  14. Herxheimer K. Über Chlorakne. Münch Med Wochenschr. 1899;46:278.Google Scholar
  15. Jansing PJ, Korff R. Blood levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin and gamma-globulins in a follow-up investigation of employees with chloracne. J Dermatol Sci. 1994;8:91–5.PubMedGoogle Scholar
  16. Ju Q, Yang KC, Zouboulis CC, et al. Chloracne: from clinic to research. Dermatol Sin. 2012;30:2–6.Google Scholar
  17. McDonagh AJ, Gawkrodger DJ, Walger AE. Chloracne—study of an outbreak with new clinical observations. Clin Exp Dermatol. 1993;18:523–5.PubMedGoogle Scholar
  18. Mitoma C, Mine Y, Utani A, et al. Current skin symptoms of Yusho patients exposed to high levels of 2,3,4,7,8-pentachlorinated dibenzofuran and polychlorinated biphenyls in 1968. Chemosphere. 2015;137:45–51.PubMedGoogle Scholar
  19. Moses M, Prioleau PG. Cutaneous histologic findings in chemical workers with and without chloracne with past exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Am Acad Dermatol. 1985;12:497–506.PubMedGoogle Scholar
  20. Niu YM, Hao FT, Xia YJ. Sodium 3,5,6-trichloropyridin-2-ol poisoning: report of four cases. Toxicol Ind Health. 2014;30:475–9.PubMedGoogle Scholar
  21. Patterson AT, Kaffenberger BH, Keller RA, Elston DM. Skin diseases associated with agent orange and other organochlorine exposures. J Am Acad Dermatol. 2016;74:143–70.PubMedGoogle Scholar
  22. Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev. 2001;23:231–47.PubMedGoogle Scholar
  23. Poskitt LB, Duffill MB, Rademaker M. Chloracne, palmoplantar keratoderma and localized scleroderma in a weed sprayer. Clin Exp Dermatol. 1994;19:264–7.PubMedGoogle Scholar
  24. Rosas-Vazquez E, Campos-Macias P, Ochoa-Tirado JG, et al. Chloracne in the 1990s. Int J Dermatol. 1996;35:643–5.PubMedGoogle Scholar
  25. Ruiz-Méndez MV. Contribution of denaturing and deodorization processes of oils to toxic oil syndrome. Chem Biol Interact. 2011;192:142–4.PubMedGoogle Scholar
  26. Saurat JH. Strategic targets in acne: the comedone switch in question. Dermatology. 2015;231:105–11.PubMedGoogle Scholar
  27. Saurat JH, Sorg O. Chloracne, a misnomer and its implications. Dermatology. 2010;221:23–6.PubMedGoogle Scholar
  28. Saurat JH, Kaya G, Saxer-Sekulic N, et al. The cutaneous lesions of dioxin exposure: lessons from the poisoning of Victor Yushchenko. Toxicol Sci. 2012;125:310–7.PubMedGoogle Scholar
  29. Scerri L, Zaki I, Millard LG. Severe halogen acne due to a trifluoromethylpyrazole derivative and its resistance to isotretinoin. Br J Dermatol. 1995;132:144–8.PubMedGoogle Scholar
  30. Seghal VN, Ghorpade A. Fume inhalation chloracne. Dermatologica. 1983;167:33–6.Google Scholar
  31. Sorg O. Tobacco smoke and chloracne: an old story comes to light. Dermatology. 2015;231:297.PubMedGoogle Scholar
  32. Sorg O, Zennegg M, Schmid P, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCCD) poisoning in Victor Yushchenko: identification and measurement of TCCD metabolites. Lancet. 2009;374:1179–85.PubMedGoogle Scholar
  33. Tindall JP. Chloracne and chloracnegens. J Am Acad Dermatol. 1985;13:539–58.PubMedGoogle Scholar
  34. Urabe H, Kodak H. The dermal symptomatology of Yusho. In: Higuchi K, editor. PCB poisoning and pollution. New York: Academic; 1976. p. 105–23.Google Scholar
  35. Wong CK, Chen CJ, Cheng PC, Chen PH. Mucocutaneous manifestations of polychlorinated biphenyls (PCB) poisoning: a study of 122 cases in Taiwan. Br J Dermatol. 1982;107:317–23.PubMedGoogle Scholar

Gram-Negative Folliculitis

  1. Bachmeyer C, Landgraf N, Cordier F, et al. Acinetobacter baumanii folliculitis in a patient with AIDS. Clin Exp Dermatol. 2005;30:256–8.PubMedGoogle Scholar
  2. Blankenship ML. Gram-negative folliculitis: follow-up observations in 20 patients. Arch Dermatol. 1984;120:1301–3.PubMedGoogle Scholar
  3. Feibleman CE, Rasmussen JE. Gram-negative acne. Cutis. 1980;25:194–9.PubMedGoogle Scholar
  4. Fulton JE Jr, McGinley K, Leyden J, Marples R. Gram-negative folliculitis in acne vulgaris. Arch Dermatol. 1968;98:349–53.PubMedGoogle Scholar
  5. James WD, Leyden JJ. Treatment of gram-negative folliculitis with isotretinoin: positive clinical and microbiologic response. J Am Acad Dermatol. 1985;12:319–24.PubMedGoogle Scholar
  6. Leyden JJ, Marples RR, Mills OH Jr, Kligman AM. Gram-negative folliculitis—a complication of antibiotic therapy of acne vulgaris. Br J Dermatol. 1973;88:533–8.PubMedGoogle Scholar
  7. Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res. 1986;278:307–13.PubMedGoogle Scholar
  8. Neubert U, Jansen T, Plewig G. Bacteriologic and immunologic aspects of gram-negative folliculitis: a study of 46 patients. Int J Dermatol. 1999;38:270–4.PubMedGoogle Scholar
  9. Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol. 1982a;6:766–85.PubMedGoogle Scholar
  10. Raia DD, Barbareschi M, Veraldi S. Citrobacter koseri folliculitis of the face. Infection. 2015;43:595–7.PubMedGoogle Scholar
  11. Simjee S, Sahm DF, Soltani K, Morello JA. Organisms associated with gram-negative folliculitis: in vitro growth in the presence of isotretinoin. Arch Dermatol Res. 1986;278:314–6.PubMedGoogle Scholar
  12. Weissmann A, Wagner A, Plewig G. Reduction of bacterial skin flora during oral treatment of severe acne with 13-cis-retinoic acid. Arch Dermatol Res. 1981;270:179–83.PubMedGoogle Scholar

Malassezia Folliculitis

  1. Ayhan M, Sancak B, Karaduman A, et al. Colonization of neonate skin by Malassezia species: relationship with neonatalcephalic pustulosis. J Am Acad Dermatol. 2007;57:1012–8.PubMedGoogle Scholar
  2. Bernier V, Weill FX, Hirigoyen V, et al. Skin colonization by Malassezia species in neonates: a prospective study and relationship with neonatal cephalic pustulosis. Arch Dermatol. 2002;138:215–8.PubMedGoogle Scholar
  3. Budavari JM, Grayson W. Papular follicular eruptions in human immunodeficiency virus-positive patients in South Africa. Int J Dermatol. 2007;46:706–10.PubMedGoogle Scholar
  4. Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31:455–63.PubMedGoogle Scholar
  5. Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. J Dermatol. 2015;42:250–7.PubMedGoogle Scholar
  6. Jolly J. Notice sur la vie et les travaux de Louis Malassez. C R Soc Biol. 1910;68:1–18.Google Scholar
  7. Nenoff P, Krüger C, Mayser P. Kutane Malassezia-Infektionen und Malassezia-assoziierte Dermatosen: Ein Update. Hautarzt. 2015;66:465–84.PubMedGoogle Scholar
  8. Prindaville B, Belazarian L, Levin NA, Wiss K. Pityrosporum folliculitis: a retrospective review of 110 cases. J Am Acad Dermatol. 2018;78:511–4.PubMedGoogle Scholar
  9. Tsai YC, Wang JY, Wu YH, Wang YJ. Atypical clinical presentations of Malassezia folliculitis: a retrospective analysis of 94 biopsy-proven cases. Int J Dermatol. 2018;57:e19–20.PubMedGoogle Scholar
  10. Tu WT, Chin SY, Chou CL, et al. Utility of Gram staining for diagnosis of Malassezia folliculitis. J Dermatol. 2018;45:228–31.PubMedGoogle Scholar
  11. Wu G, Zhao H, Li C, et al. Genus-wide comparative genomics of Malassezia delineates its phylogeny, physiology, and niche adaptation on human skin. PLoS Genet. 2015;11:e1005614.PubMedPubMedCentralGoogle Scholar
  12. Yu HJ, Lee SK, Son SJ, et al. Steroid acne vs. Pityrosporum folliculitis: the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int J Dermatol. 1998;37:772–7.PubMedGoogle Scholar

Acne Necrotica/Necrotizing Lymphocytic Folliculitis

  1. Boeck C. Acne frontalis s. necrotica (Acne pilaris-Bazin). Norsk Mag. f. Laegevidensk. 1888;val. iii. p. 793–812.Google Scholar
  2. Boeck C. Acne frontalis s. necrotica (Acne pilaris-Bazin) (Hierzu Tafel III). Arch Dermatol Syph. 1889;21:37–49.Google Scholar
  3. Kossard S, Collins A, McCrossin I. Necrotizing lymphocytic folliculitis: the early lesion of acne necrotica (varioliformis). J Am Acad Dermatol. 1987;16:1007–14.PubMedGoogle Scholar
  4. Milde P, Goerz G, Plewig G. Acne necrotica (varioliformis). Nekrotisierende lymphozytäre Folliculitis. Hautarzt. 1993;44:34–6.PubMedGoogle Scholar
  5. Pick FJ. Zur Kenntnis der Acne frontalis seu verioliformis (Hebra), Acne frontalis necrotica (Boeck) (Hierzu Tafel V). Arch Dermatol Syph. 1889;21:551–60.Google Scholar
  6. Pitney LK, O'Brien B, Pitney MJ. Acne necrotica (necrotizing lymphocytic folliculitis): an enigmatic and under-recognised dermatosis. Australas J Dermatol. 2018;59:e53–8.PubMedGoogle Scholar
  7. Zirn JR, Scott RA, Hambrick GW. Chronic acneiform eruption with crateriform scars: acne necrotica (varioliformis) (necrotizing lymphocytic folliculitis). Arch Dermatol. 1996;132:1367, 1370.PubMedGoogle Scholar

Pseudofolliculitis Barbae

  1. Alexander AM. Evaluation of a foil-guarded shaver in the management of pseudofolliculitis barbae. Cutis. 1981;27:534–42.PubMedGoogle Scholar
  2. Coquilla BH, Lewis CW. Management of pseudofolliculitis barbae. Mil Med. 1995;160:263–9.PubMedGoogle Scholar
  3. Crutchfield CE III. The causes and treatment of pseudofolliculitis barbae. Cutis. 1998;61:351–6.PubMedGoogle Scholar
  4. Gray J, McMichael AJ. Pseudofolliculitis barbae: understanding the condition and the role of facial grooming. Int J Cosmet Sci. 2016;38(Suppl 1):24–7.PubMedGoogle Scholar
  5. Halder RM. Pseudofolliculitis barbae and related disorders. Dermatol Clin. 1988;6:407–12.PubMedGoogle Scholar
  6. Kligman AM, Mills OH. Pseudofolliculitis of the beard and topically applied tretinoin. Arch Dermatol. 1973;107:551–2.PubMedGoogle Scholar
  7. Leheta TM. Comparative evaluation of long pulse Alexandrite laser and intense pulsed light systems for pseudofolliculitis barbae treatment with one year of follow up. Indian J Dermatol. 2009;54:364–8.PubMedPubMedCentralGoogle Scholar
  8. Nguyen TA, Patel PS, Viola KV, Friedman AJ. Pseudofolliculitis barbae in women: a clinical perspective. Br J Dermatol. 2015;173:279–81.PubMedGoogle Scholar
  9. Perricone NV. Treatment of pseudofolliculitis barbae with topical glycolic acid: a report of two studies. Cutis. 1993;52:232–5.PubMedGoogle Scholar
  10. Ross EV, Cooke LM, Timko AL, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. 2002;47:263–70.PubMedGoogle Scholar
  11. Smith EP, Winstanley D, Ross EV. Modified superlong pulse 810 nm diode laser in the treatment of pseudofolliculitis barbae in skin types V and VI. Dermatol Surg. 2005;31:297–301.PubMedGoogle Scholar
  12. Taylor SC, Barbosa V, Burgess C, et al. Hair and scalp disorders in adult and pediatric patients with skin of color. Cutis. 2017;100:31–5.PubMedGoogle Scholar
  13. Winter H, Schissel D, Parry DA, et al. An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae. J Invest Dermatol. 2004;122:652–7.PubMedGoogle Scholar

Acne Aestivalis/Mallorca Acne/Polymorphous Light Eruption

  1. Chiam LY, Chong WS. Pinpoint popular polymorphous light eruption in Asian skin: a variant in darker-skinned individuals. Photodermatol Photoimmunol Photomed. 2009;25:71–4.PubMedGoogle Scholar
  2. Hjorth N, Sjolin KE, Sylvest B, Thomsen K. Acne aestivalis—Mallorca acne. Acta Derm Venereol (Stockh). 1972;52:61–3.Google Scholar
  3. Kontos AP, Cusack CA, Chaffins M, Lim HW. Polymorphous light eruption in African Americans: pinpoint papular variant. Photodermatol Photoimmunol Photomed. 2002;18:303–6.PubMedGoogle Scholar
  4. Mills OH Jr, Kligman AM. Acne aestivalis. Arch Dermatol. 1975b;111:891–2.PubMedGoogle Scholar
  5. Nielson EB, Thorman J. Acne-like eruptions induced by PUVA treatment. Acta Derm Venereol (Stockh). 1978;58:374–5.Google Scholar
  6. Salomon N, Messer G, Dick D, et al. Phototesting for polymorphic light eruption (PLE) with consecutive UVA1/UVB-irradiation. Photodermatol Photoimmunol Photomed. 1997;13:72–4.PubMedGoogle Scholar
  7. Sjolin KE. Acne aestivalis. A histopathological study. Acta Derm Venereol (Stockh). 1979;59:171–6.Google Scholar

Atrophodermia Vermiculata/Atrophoderma Vermiculatum

  1. Baden HP, Byers HR. Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans. Arch Dermatol. 1994;130:469–75.PubMedGoogle Scholar
  2. Bassioukas K, Fragidou M, Nakuci M, et al. Atrophodermia vermiculata. Cutis. 1997;59:337–40.PubMedGoogle Scholar
  3. Carol WLL, Godfried EG, Prakken JR, Prick JJGV. Recklinghausensche Neurofibromatosis, Atrophodermia vermiculata und kongenitale Herzanomalie als Hauptkennzeichen eines familiaer-hereditaeren Syndroms. Dermatologica. 1940;81:345–65.Google Scholar
  4. Darier J. Atrophodermie vermiculée des joues avec kératoses follikulaires. Bull Soc Franc Derm Syph. 1920;27:345.Google Scholar
  5. Frosch PJ, Brumage MR, Schuster-Pavlovic C, Bersch A. Atrophoderma vermiculatum. J Am Acad Derm. 1988;18:538–42.PubMedGoogle Scholar
  6. Heidingsfeld ML. Atrophia maculosa varioliformis cutis. J Cutan Dis. 1918;36:285–8.Google Scholar
  7. Köse O, Safali M, Riza Gür A. Atrophoderma vermiculatum with Melkersson-Rosenthal syndrome. Dermatology. 2005;210:76–7.PubMedGoogle Scholar
  8. Noh S, Roh HJ, Jin S, et al. Atrophia maculosa varioliformis cutis with histological features of perifollicular elastolysis. Eur J Dermatol. 2012;22:703–4.PubMedGoogle Scholar
  9. Oranje AP, van Osch LD, Oosterwijk JC. Keratosis pilaris atrophicans. One heterogeneous disease or a symptom in different clinical entities? Arch Dermatol. 1994;130:500–2.PubMedGoogle Scholar
  10. Pernet G. Atrophodermia reticulata symmetrica faciei. Med Press. 1916;101:487.Google Scholar
  11. Unna PG. Ulerythema acneiforme Unna. In: Leloir (Lille), editors. International atlas of rare skin diseases. Moris (London), Unna (Hamburg), Duhring (Philadelphia). Voss, Hamburg. Part II, plate 2, delivered March 29, 1890.Google Scholar
  12. van Dijk FS, Brittain H, Boerma R, et al. Atrophoderma vermiculatum: a cutaneous feature of Loeys-Dietz syndrome. JAMA Dermatol. 2015;151:675–7.PubMedGoogle Scholar

Radiation-Induced Acne/Comedones

  1. Aversa AJ, Nagy R. Localized comedones following radiation therapy. Cutis. 1983;31:296–303.PubMedGoogle Scholar
  2. Finn OA. Localised acneiform eruption following X-ray irradiation. Br J Clin Pract. 1981;35:57–8.PubMedGoogle Scholar
  3. Hepburn NC, Crellin RP, Beveridge GW, et al. Localized acne as a complication of megavoltage radiotherapy. J Dermatol Treat. 1992;3:137–8.Google Scholar
  4. Hoff NP, Reifenberger J, Bölke E, et al. Strahleninduzierter Morbus Favre-Racouchot. Hautarzt. 2012;63:766–7.PubMedGoogle Scholar
  5. Jansen T, Peter RU, Plewig G. Komedonen nach ionisierenden Strahlen. Akt Dermatol. 1996;22:210–2.Google Scholar
  6. Myskowski PL, Safai B. Localized comedo formation after cobalt irradiation. Int J Dermatol. 1981;20:550–1.PubMedGoogle Scholar
  7. Stein KM, Leyden JJ, Goldschmidt H. Localized acneiform eruption following cobalt irradiation. Br J Dermatol. 1972;87:274–9.PubMedGoogle Scholar
  8. Trunnell TN, Baer RL, Michaelides P. Acneiform changes in areas of cobalt irradiation. Arch Dermatol. 1972;106:73–5.PubMedGoogle Scholar

Solar Comedones/Favre-Racouchot Disease

  1. Favre M, Racouchot J. L’ élastéidose cutanée nodulaire a kystes et a comédons. Ann Dermatol Syph. 1951;78:681–702.Google Scholar
  2. Kligman AM, Plewig G, Mills OH Jr. Topically applied tretinoin for senile (solar) comedones. Arch Dermatol. 1971;104:420–1.PubMedGoogle Scholar
  3. Mavilia L, Campolmi P, Santoro G, Lotti T. Combined treatment of Favre-Racouchot syndrome with a superpulsed carbon dioxide laser: report of 50 cases. Dermatol Ther. 2010;23(Suppl 1):S4–6.PubMedGoogle Scholar
  4. Mohs E, McCall MW, Greenway HT. Curettage for removal of the comedones and cysts of the Favre-Racouchot syndrome. Arch Dermatol. 1982;118:365–6.PubMedGoogle Scholar
  5. Plewig G, Braun-Falco O. Behandlung von Comedonen bei Morbus Favre-Racouchot und Acne venenata mit Vitamin A-Säure. Hautarzt. 1971;22:341–5.PubMedGoogle Scholar
  6. Turner E, Grube C. M. Favre-Racouchot -- unilaterale Variante. Aktuel Dermatol. 1990;16:286–7.Google Scholar

Comedo-Like Eruptions

  1. Cantu JM, Gomez-Bustamante MO, Gonzalez-Mendoza A, Sanchez-Corona J. Familial comedones: evidence for autosomal dominant inheritance. Arch Dermatol. 1978;114:1807–9.PubMedGoogle Scholar
  2. Cheng MJ, Chen W, Happle R, Song ZQ. Familial disseminated comedones without dyskeratosis: report of an affected family and review of the literature. Dermatology. 2014;228:303–6.PubMedGoogle Scholar
  3. Cho SB, Lee SH, Jung JY, Oh SH. A case of childhood flexural comedones. J Eur Acad Dermatol Venereol. 2009;23:366–7.PubMedGoogle Scholar
  4. Hall JR, Holder W, Knox JM, et al. Familial dyskeratotic comedones. A report of three cases and review of the literature. J Am Acad Dermatol. 1987;17:808–14.PubMedGoogle Scholar
  5. Ito T, Yoshida Y, Furue M, Yamamoto O. Multiple congenital comedones, hearing impairment and intellectual disability: a new syndromic association? Eur J Dermatol. 2012;22:807–8.PubMedGoogle Scholar
  6. Kumaran MS, Appachu D, Jayaseelan E. Familial dyskeratotic comedones. Indian J Dermatol Venereol Leprol. 2008;74:142–4.PubMedGoogle Scholar
  7. Larralde M, Abad ME, Muñoz AS, Luna P. Childhood flexural comedones: a new entity. Arch Dermatol. 2007;143:909–11.PubMedGoogle Scholar
  8. Plewig G, Christophers E. Nevoid follicular epidermolytic hyperkeratosis. Arch Dermatol. 1975;111:223–6.PubMedGoogle Scholar
  9. Powell PR, Garza-Chapa JI, Susa JS, Weis SE. Perianal comedones: a rare incidental finding. Case Rep Dermatol Med. 2017;2017:9019682.PubMedPubMedCentralGoogle Scholar
  10. Rerknimitr P, Korkij W, Wititsuwannakul J, et al. Expanding phenotypic spectrum of familial comedones. Dermatology. 2014;228:215–9.PubMedGoogle Scholar
  11. Rodin HH, Blankenship ML, Bernstein G. Diffuse familial comedones. Arch Dermatol. 1967;95:145–6.Google Scholar
  12. Ständer S, Rütten A, Metze D. Familiäre dyskeratotische Komedonen. Eine seltene Entität. Hautarzt. 2001;52:533–6.PubMedGoogle Scholar
  13. Van Geel NA, Kockaert M, Neumann HA. Familial dyskeratotic comedones. Br J Dermatol. 1999;140:956–9.PubMedGoogle Scholar
  14. Vano-Galvan S, Hernández-Martín A, Colmenero I, Torrelo A. Disseminated congenital comedones. Pediatr Dermatol. 2011;28:58–9.PubMedGoogle Scholar
  15. Zhou C, Wen GD, Soe LM, et al. Novel mutations in PSENEN gene in two Chinese acne inversa families manifested as familial multiple comedones and Dowling-Degos disease. Chin Med J (Engl). 2016;129:2834–9.Google Scholar

Steatocystoma Multiplex

  1. Ahn SK, Chung J, Lee WS, et al. Hybrid cysts showing alternate combination of eruptive vellus hair cyst, steatocystoma multiplex, and epidermoid cyst, and an association among the three conditions. Am J Dermatopathol. 1996;18:645–9.PubMedGoogle Scholar
  2. Bosellini PL. Beitrag zur Lehre von den multiplen, folliculären Hautcysten. (Hierzu Taf. III-V.). Arch Dermatol Syph. 1898;45:81–96.Google Scholar
  3. Brownstein MH. Steatocystoma simplex: a solitary steatocystoma. Arch Dermatol. 1982;118:409–11.PubMedGoogle Scholar
  4. Cambiaghi S, Riva S, Ramaccioni V, et al. Steatocystoma multiplex and leuconychia in a child with Alagille syndrome. Br J Dermatol. 1998;138:150–4.PubMedGoogle Scholar
  5. Covello SP, Smith FJD, Sillevis Smith JH, et al. Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia congenita type 2. Br J Dermatol. 1998;139:475–80.PubMedGoogle Scholar
  6. de Almeida HL, Basso P. Linear unilateral steatocystoma multiplex. J Eur Acad Dermatol Venereol. 2009;23:213–4.PubMedGoogle Scholar
  7. Fernandez-Flores A, Cuesta CC, García CS, del Río JS. Steatocystoma multiplex associated with bilateral preauricular sinuses. J Cutan Pathol. 2014;41:677–9.PubMedGoogle Scholar
  8. Gass JK, Wilson NJ, Smith FJ, et al. Steatocystoma multiplex, oligodontia and partial persistent primary dentition associated with a novel keratin 17 mutation. Br J Dermatol. 2009;161:1396–8.PubMedGoogle Scholar
  9. Gianotti R, Cavicchini S, Alessi E. Simultaneous occurrence of multiple trichoblastomas and steatocystoma multiplex. Am J Dermatopathol. 1997;19:294–8.PubMedGoogle Scholar
  10. Holmes R, Black MM. Steatocystoma multiplex with unusually prominent cysts on the face. Br J Dermatol. 1980;102:711–3.PubMedGoogle Scholar
  11. Jamieson WA. Case of numerous cutaneous cysts scattered over the body. Edinburgh Med J. 1873;19:223–34.Google Scholar
  12. Jeong SY, Kim JH, Seo SH, et al. Giant steatocystoma multiplex limited to the scalp. Clin Exp Dermatol. 2009;34:e318–9.PubMedGoogle Scholar
  13. Kim JU, Nogita T, Terajima S, Kawashima M. Pachyonychia congenita associated with steatocystoma multiplex. J Dermatol. 1998;25:479–81.PubMedGoogle Scholar
  14. Kromann CB, Zarchi K, Nürnberg BM, Jemec GB. Recurring axillary, abdominal and genitofemoral nodules and abscesses. Hereditary steatocystoma multiplex. Acta Derm Venereol. 2015;95:121–3.PubMedGoogle Scholar
  15. Marzano AV, Tavecchio S, Balice Y, et al. Acral subcutaneous steatocystoma multiplex: a distinct subtype of the disease? Australas J Dermatol. 2012;53:198–201.PubMedGoogle Scholar
  16. Nishimura M, Kohda H, Urabe A. Steatocystoma multiplex: a facial papular variant. Arch Dermatol. 1986;122:205–7.PubMedGoogle Scholar
  17. Pietrzak A, Bartosinska J, Filip AA, et al. Steatocystoma multiplex with hair shaft abnormalities. J Dermatol. 2015;42:521–3.PubMedGoogle Scholar
  18. Plewig G, Wolff HH, Braun-Falco O. Steatocystoma multiplex: anatomic reevaluation, electron microscopy, and autoradiography. Arch Dermatol Res. 1982b;272:363–80.PubMedGoogle Scholar
  19. Pringle JJ. A case of peculiar multiple sebaceous cysts (steatocystoma multiplex). Br J Dermatol. 1899;11:381–8.Google Scholar
  20. Procianoy F, Golbert MB, Golbspan L, et al. Steatocystoma simplex of the eyelid. Ophthal Plast Reconstr Surg. 2009;25:147–8.PubMedGoogle Scholar
  21. Rongioletti F, Cattarini G, Romanelli P. Late onset vulvar steatocystoma multiplex. Clin Exp Dermatol. 2002;27:445–7.PubMedGoogle Scholar
  22. Santana CN, Pereira DD, Lisboa AP, et al. Steatocystoma multiplex suppurativa: case report of a rare condition. An Bras Dermatol. 2016;91(5 Suppl 1):51–3.PubMedPubMedCentralGoogle Scholar
  23. Schwarz JL, Goldsmith LA. Steatocystoma multiplex suppurativum: treatment with isotretinoin. Cutis. 1984;34:149–53.Google Scholar
  24. Yoneda K, Nakai K, Demitsu T, Kubota Y. Polycystic kidney disease with steatocystoma multiplex: evidences for a disruptive effect of mutated polycystin-1 on keratin 17 polymerisation. Acta Derm Venereol. 2015;95:353–4.PubMedGoogle Scholar

Eruptive Vellus Hair Cyst

  1. Cheng H, Sohal S, Cheung K. Eruptive vellus hair cysts of the vulva. Australas J Dermatol. 2017;58:e254–5.PubMedGoogle Scholar
  2. Esterly NB, Fretzin DF, Pinkus H. Eruptive vellus hair cysts. Arch Dermatol. 1977;113:500–3.PubMedGoogle Scholar
  3. Fisher DA. Retinoic acid in the treatment of eruptive vellus hair cysts. J Am Acad Dermatol. 1981;5:221.PubMedGoogle Scholar
  4. Kiene P, Hauschield A, Christophers E. Eruptive vellus hair cysts and steatocystoma multiplex. Variants of one entity? Br J Dermatol. 1996;134:365–7.PubMedGoogle Scholar
  5. Köse O, Taştan HB, Deveci S, Gür AR. Anhidrotic ectodermal dysplasia with eruptive vellus hair cysts. Int J Dermatol. 2001;40:401–2.PubMedGoogle Scholar
  6. Mayron R, Grimwood RE. Familial occurrence of eruptive vellus hair cysts. Pediatr Dermatol. 1988;5:94–6.PubMedGoogle Scholar
  7. Mieno H, Fujimoto N, Tajima S. Eruptive vellus hair cyst in patients with chronic renal failure. Dermatology. 2004;208:67–9.PubMedGoogle Scholar
  8. Nandedkar MA, Minus H, Nandedkar MA. Eruptive vellus hair cysts in a patient with Lowe syndrome. Pediatr Dermatol. 2004;21:54–7.PubMedGoogle Scholar
  9. Ohtake N, Kubota Y, Takayama O, et al. Relationship between steatocystoma multiplex and eruptive vellus hair cysts. J Am Acad Dermatol. 1992;26:876–8.PubMedGoogle Scholar
  10. Ponzo MG, Van Allen MI, Armstrong L, et al. Case series: a kindred with eruptive vellus hair cysts and systemic features. J Cutan Med Surg. 2017;21:564–7.PubMedGoogle Scholar
  11. Sanchez Yus E, Requena L. Eruptive vellus hair cysts and steatocystoma multiplex. Am J Dermatopathol. 1990;12:536–7.PubMedGoogle Scholar

Trichostasis Spinulosa

  1. Brajac I. Familiar occurrence of multiple primary epidermoid cysts and trichostasis spinulosa: a novel skin phenotype associated with inherited sensorineural deafness. J Eur Acad Dermatol Venereol. 2010;24:362–3.PubMedGoogle Scholar
  2. Kailasam V, Kamalam A, Thambiah AS. Trichostasis spinulosa. Int J Dermatol. 1979;18:297–300.PubMedGoogle Scholar
  3. Lazarov A, Amichai B, Cagnano M, Halevy S. Coexistence of trichostasis spinulosa and eruptive vellus hair cysts. Int J Dermatol. 1994;33:858–9.PubMedGoogle Scholar
  4. Mills OH Jr, Kligman AM. Topically applied tretinoin in the treatment of trichostasis spinulosa. Arch Dermatol. 1973;108:378–80.PubMedGoogle Scholar
  5. Navarini AA, Ziegler M, Kolm I, et al. Minoxidil-induced trichostasis spinulosa of terminal hair. Arch Dermatol. 2010;146:1434–5.PubMedGoogle Scholar
  6. Nobl G. Trichostasis spinulosa. Arch Dermatol Syphil. 1913;114:611–27.Google Scholar
  7. Pozo L, Bowling J, Perrett CM, et al. Dermoscopy of trichostasis spinulosa. Arch Dermatol. 2008;144:1088.PubMedGoogle Scholar
  8. Sidwell RU, Francis N, Bunker CB. Diffuse trichostasis spinulosa in chronic renal failure. Clin Exp Dermatol. 2006;31:86–8.PubMedGoogle Scholar
  9. Young MC, Jorizzo JL, Sanchez RL, et al. Trichostasis spinulosa. Int J Dermatol. 1985;24:575–80.PubMedGoogle Scholar

Dilated Pore Winer

  1. Ba W, Wang W, Li C. An unusual location of a pilar sheath acanthoma. Int J Trichology. 2015;7:179–81.PubMedPubMedCentralGoogle Scholar
  2. Bhawan J. Pilar sheath acanthoma. A new benign follicular tumor. J Cutan Pathol. 1979;6:438–40.PubMedGoogle Scholar
  3. Jo-Velasco M, Corrales-Rodríguez A, Francés-Rodríguez L, Alegría-Landa V, et al. Plaque-like pilar sheath acanthoma: histopathologic and immunohistochemical study of 3 unusual cases. Am J Dermatopathol. 2018;40:125–30.PubMedGoogle Scholar
  4. Klövekorn G, Klövekorn W, Plewig G, Pinkus H. Riesenpore und Haarscheidenakanthom. Klinische und histologische Diagnose. Hautarzt. 1983;34:209–16.PubMedGoogle Scholar
  5. Mehregan AH, Brownstein MH. Pilar sheath acanthoma. Arch Dermatol. 1978;114:1495–7.PubMedGoogle Scholar
  6. Walsh SN, Cruz DJ, Hurt MA. Hair cortex comedo: a series of 34 cases. Am J Dermatopathol. 2010;32:749–54.PubMedGoogle Scholar
  7. Winer LH. The dilated pore, a trichoepithelioma. J Invest Dermatol. 1954;23:181–8.PubMedGoogle Scholar

Miliary Osteoma Cutis

  1. Basler RS, Taylor WB, Peacor DR. Postacne osteoma cutis: X-ray diffraction analysis. Arch Dermatol. 1974;110:113–4.PubMedGoogle Scholar
  2. Burgdorf W, Nasemann T. Cutaneous osteomas: a clinical and histopathological review. Arch Dermatol Res. 1977;260:121–35.PubMedGoogle Scholar
  3. Fawcett HA, Marsden RA. Hereditary osteoma cutis. J R Soc Med. 1983;76:697–9.PubMedPubMedCentralGoogle Scholar
  4. Kim D, Franco GA, Shigehara H, et al. Benign miliary osteoma cutis of the face: a common incidental CT finding. AJNR Am J Neuroradiol. 2017;38:789–94.PubMedGoogle Scholar
  5. Moritz DL, Elewski B. Pigmented postacne osteoma cutis in a patient treated with minocycline: report and review of the literature. J Am Acad Dermatol. 1991;24:851–3.PubMedGoogle Scholar
  6. Myllylä RM, Haapasaari KM, Palatsi R, et al. Multiple miliary osteoma cutis is a distinct disease entity: four case reports and review of the literature. Br J Dermatol. 2011;164:544–52.PubMedGoogle Scholar
  7. Ochsendorf FR, Kaufmann R. Erbium: YAG laser-assisted treatment of miliary osteoma cutis. Br J Dermatol. 1998;138:371–2.PubMedGoogle Scholar
  8. Oikarinen A, Tuomi ML, Kallionen M, et al. A study of bone formation in osteoma cutis employing biochemical, histochemical and in situ hybridization techniques. Acta Derm Venereol (Stockh). 1992;72:172–4.Google Scholar
  9. Ratnavel RC, Burrows NP, Pye RJ. Osteoma cutis as a sequela of acne. J R Soc Med. 1994;87:107–8.PubMedPubMedCentralGoogle Scholar
  10. Riahi RR, Cohen PR. Multiple miliary osteoma cutis of the face after initiation of alendronate therapy for osteoporosis. Skinmed. 2011;9:258–9.PubMedGoogle Scholar
  11. Safi Y, Valizadeh S, Vasegh S, et al. Prevalence of osteoma cutis in the maxillofacial region and classification of its radiographic pattern in cone beam CT. Dermatol Online J. 2016;15:22.Google Scholar
  12. Smith CG, Glaser DA. Treatment of multiple miliary osteoma cutis with tretinoin gel. J Am Acad Dermatol. 1999;41(3 Pt 1):500.PubMedGoogle Scholar
  13. Walter JF, Macknet KD. Pigmentation of osteoma cutis caused by tetracycline. Arch Dermatol. 1979;115:1087–8.PubMedGoogle Scholar
  14. Ward S, Sugo E, Verge CF, Wargon O. Three cases of osteoma cutis occurring in infancy. A brief overview of osteoma cutis and its association with pseudo-pseudohypoparathyroidism. Australas J Dermatol. 2011;52:127–31.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gerd Plewig
    • 1
  • Bodo Melnik
    • 2
  • WenChieh Chen
    • 3
  1. 1.Department of Dermatology and AllergyLudwig-Maximilian-University MunichMunichGermany
  2. 2.Department of Dermatology, Environmental Medicine and Health TheoryUniversity of OsnabrückOsnabrückGermany
  3. 3.Department of Dermatology and AllergyTechnical University of MunichMunichGermany

Personalised recommendations